Keith Lenden

Mr. Lenden is a senior advisor to Autobahn Therapeutics. He is also a co-founder.

In addition to his role at Autobahn, Mr. Lenden is a venture partner at ARCH Venture Partners. Mr.Lenden is a seasoned entrepreneur and leader in the biotechnology and pharmaceutical industries with a proven track record in company formation, executive and project leadership, corporate development and product and market strategy. Mr. Lenden was a co-founder of Receptos, Inc., a multiple sclerosis biology and GPCR drug discovery company acquired by Celgene (now BMS), Abide Therapeutics, Inc., a cannabinoid biology and serine hydrolase drug discovery company acquired by H. Lundbeck A/S, and Boundless Bio, Inc., an ecDNA cancer biology and drug discovery company. Mr. Lenden has served in a wide range of executive and product leadership roles for both public and private biopharmaceutical companies over the years, including Esperion Therapeutics, Inc., Maxygen, Inc., Acologix, Inc. and Genteric, Inc. Mr. Lenden started his career in biotechnology as a consultant at LEK Consulting. Mr. Lenden holds an MBA from the Haas School of Business at the University of California, Berkeley where he was selected as a Price Institute for Entrepreneurial Studies Venture Capital Fellow. Mr. Lenden also holds and A.B. and B.E. from the Thayer School of Engineering at Dartmouth College. Mr. Lenden is a Kauffman Fellow where he received the Jeff Timmons Leadership Award.